Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532523 | NSE: BIOCON

NSE BSE
370.20
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  361.00
  •  371.40
  •  360.10
  •  361.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7658844
  •  28184.64
  •  395.80
  •  231.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 38,797.39
  • 27.29
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 52,852.79
  • 0.15%
  • 1.87

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.47%
  • 14.57%
  • FII
  • DII
  • Others
  • 5.93%
  • 14.20%
  • 3.19%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.92
  • 18.55
  • 21.71

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.47
  • 20.52
  • 16.45

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.47
  • 5.64
  • 16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 58.54
  • 62.44
  • 59.40

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.84
  • 4.39
  • 3.02

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.10
  • 19.62
  • 15.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
3,590.40
3,462.30
3.70%
3,432.90
3,422.60
0.30%
3,917.10
3,773.90
3.79%
3,953.70
2,941.10
34.43%
Expenses
2,905.00
2,720.70
6.77%
2,812.50
2,708.20
3.85%
3,001.20
2,776.60
8.09%
3,026.90
2,296.80
31.79%
EBITDA
685.40
741.60
-7.58%
620.40
714.40
-13.16%
915.90
997.30
-8.16%
926.80
644.30
43.85%
EBIDTM
19.09%
21.42%
18.07%
20.87%
23.38%
26.43%
23.44%
21.91%
Other Income
32.50
157.90
-79.42%
1,134.50
93.50
1,113.37%
48.60
154.90
-68.62%
565.50
78.60
619.47%
Interest
225.60
247.70
-8.92%
236.00
233.00
1.29%
227.00
248.80
-8.76%
266.70
120.30
121.70%
Depreciation
419.90
389.30
7.86%
405.40
358.00
13.24%
407.00
363.70
11.91%
414.50
301.10
37.66%
PBT
98.40
238.50
-58.74%
1,145.50
216.90
428.12%
321.70
536.70
-40.06%
832.30
30.10
2,665.12%
Tax
71.30
41.60
71.39%
283.70
34.80
715.23%
96.10
82.10
17.05%
54.90
-4.80
-
PAT
27.10
196.90
-86.24%
861.80
182.10
373.26%
225.60
454.60
-50.37%
777.40
34.90
2,127.51%
PATM
0.75%
5.69%
25.10%
5.32%
5.76%
12.05%
19.66%
1.19%
EPS
-0.13
1.05
-
5.49
0.84
553.57%
1.13
2.61
-56.70%
5.50
-0.35
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
14,894.10
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
Net Sales Growth
9.52%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
 
Cost Of Goods Sold
4,926.60
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
Gross Profit
9,967.50
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
GP Margin
66.92%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
Total Expenditure
11,745.60
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
Power & Fuel Cost
-
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
% Of Sales
-
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
Employee Cost
-
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
% Of Sales
-
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
Manufacturing Exp.
-
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
% Of Sales
-
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
General & Admin Exp.
-
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
% Of Sales
-
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
Selling & Distn. Exp.
-
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
% Of Sales
-
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
Miscellaneous Exp.
-
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
108.70
% Of Sales
-
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
EBITDA
3,148.50
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
EBITDA Margin
21.14%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
Other Income
1,781.10
967.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
Interest
955.30
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
Depreciation
1,646.80
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
PBT
2,397.90
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
Tax
506.00
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
Tax Rate
21.10%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
PAT
1,891.90
1,022.50
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
PAT before Minority Interest
1,466.00
1,297.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
Minority Interest
-425.90
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
PAT Margin
12.70%
6.93%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
PAT Growth
117.84%
120.99%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
 
EPS
15.76
8.52
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
Share Capital
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
Total Reserves
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
Non-Current Liabilities
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
Secured Loans
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
Unsecured Loans
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
Long Term Provisions
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
Current Liabilities
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
Trade Payables
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
Other Current Liabilities
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
Short Term Borrowings
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
Short Term Provisions
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
Total Liabilities
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
Net Block
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
Gross Block
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
Accumulated Depreciation
7,287.40
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
Non Current Assets
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
Capital Work in Progress
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
Non Current Investment
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
Long Term Loans & Adv.
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
Other Non Current Assets
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
Current Assets
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
Current Investments
315.60
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
Inventories
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
Sundry Debtors
6,230.60
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
Cash & Bank
2,258.70
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
Other Current Assets
1,430.40
334.10
660.20
713.10
809.20
678.60
428.00
419.90
300.70
171.60
Short Term Loans & Adv.
1,096.00
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
Net Current Assets
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
Total Assets
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
PBT
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
Adjustment
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
Changes in Working Capital
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
Cash after chg. in Working capital
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
Net Fixed Assets
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
Net Investments
-47.80
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
Others
-633.50
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
Cash from Financing Activity
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
Net Cash Inflow / Outflow
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
Opening Cash & Equivalents
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
Closing Cash & Equivalent
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
ROA
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
ROE
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
ROCE
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
Fixed Asset Turnover
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
Receivable days
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
Inventory Days
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
Payable days
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
Cash Conversion Cycle
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
Total Debt/Equity
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
Interest Cover
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Biocon reports 84% fall in Q2 consolidated net profit
    31st Oct 2024, 14:26 PM

    Total consolidated income of the company increased by 0.07% at Rs 3622.90 crore for Q2FY25

    Read More
  • USFDA classifies drug substance facility of Biocon’s arm as voluntary action indicated
    31st Oct 2024, 14:09 PM

    This relates to the cGMP inspection conducted by the agency between February 20- 28, 2024

    Read More
  • Biocon - Quarterly Results
    30th Oct 2024, 17:40 PM

    Read More
  • USFDA completes surveillance inspection at Biocon’s API facility
    30th Sep 2024, 14:12 PM

    USFDA had conducted the said an inspection between September 23-27, 2024

    Read More
  • USFDA completes cGMP inspection at insulins manufacturing facility of Biocon’s arm
    30th Sep 2024, 10:42 AM

    USFDA had conducted the said an inspection between September 17-27, 2024

    Read More
  • Biocon gets EIR from USFDA for Andhra Pradesh facility
    2nd Sep 2024, 12:59 PM

    This is based on a pre-approval inspection conducted by the agency between June 10 and 14, 2024

    Read More
  • Biocon’s arm receives USFDA’s approval for Daptomycin injection
    2nd Sep 2024, 11:08 AM

    The approval further adds to Biocon’s portfolio of complex drug products

    Read More
  • Biocon’s arm secures approval from USFDA for Sacubitril/Valsartan Tablets
    2nd Sep 2024, 10:40 AM

    The approval further adds to Biocon’s portfolio of vertically integrated, complex drug products

    Read More
  • Biocon’s arm to commercialize Bmab 1200 in global markets
    29th Aug 2024, 12:27 PM

    Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.